Patent US4115538A successfully refreshed from Google Patents.
US4115538A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assay kit for cAMP and/or cGMP and method of using the same
Assignee: YAMASU SHOYU KK
•
Filing: 1977-02-07
•
Granted: 1978-09-19
•
Expires: 1997-02-07
Abstract
Abstract An assay kit for assaying adenosine-3',5'-cyclic monophosphate, which is herein referred to as cAMP, guanosine-3',5'-cyclic monophosphate, which is herein referred to as a cGMP, or both; and said assay kit comprising, A container of Reagent 1 comprising succinyl cAMP tyrosine methyl ester; succinyl cGMP tyrosine methyl ester; succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in admixture or both succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in separate containers, said esters labelled with radioactive iodine; A container of Reagent 2 comprising an anti-cAMP serum, an anti-cGMP serum, an anti-cAMP and anti-cGMP serum in admixture or both anti-cAMP serum and anti-cGMP serum in separate containers; A container of Reagent 3 comprising an imidazole buffer solution of 0.1 M or higher concentration; A container of Reagent 4 comprising a material for separation; A container of Reagent 5 comprising a solution of succinic anhydride in an organic solvent; A container of Reagent 6 comprising an organic tertiary amine; and A container of Reagent 7 comprising a standard solution of cAMP, cGMP, cAMP and cGMP in admixture or both cAMP and cGMP in separate containers.
Inventors
- 👤 Tomokazu Satoh
- 👤 Junichi Takezawa
- 👤 Akira Kuninaka
- 👤 Miyuki Honma
- 👤 Michio Ui
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 18:16
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/536; G01N33/537; G01N33/5308; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/807; Y10S436/808; Y10S436/815; Y10S436/826
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
173 words
An assay kit for assaying adenosine-3',5'-cyclic monophosphate, which is herein referred to as cAMP, guanosine-3',5'-cyclic monophosphate, which is herein referred to as cGMP, or both; and said assay kit comprising, a container of Reagent 1 comprising succinyl cAMP tyrosine methyl ester; succinyl cGMP tyrosine methyl ester; succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in admixture or both succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in separate containers, said esters labeled with radioactive iodine; a container of Reagent 2 comprising anti-cAMP serum; anti-cGMP serum; anti-cAMP and anti-cGMP serum in admixture or both anti-cAMP serum and anti-cGMP serum in separate containers; a container of Reagent 3 comprising an imidazole buffer solution of 0.1 M or higher concentration; a container of Reagent 4 comprising a material for separation; a container of Reagent 5 comprising a solution of succinic anhydride in an organic solvent; a container of Reagent 7 comprising a standard solution of cAMP; cGMP; cAMP and cGMP in admixture or both cAMP and cGMP in separate containers.
Claim 2
Dependent Claim
173 words
An assay kit for assaying adenosine-3',5'-cyclic monophosphate, which is herein referred to as cAMP, guanosine-3',5'-cyclic monophosphate, which is herein referred to as cGMP, or both; and said assay kit comprising, a container of Reagent 1 comprising succinyl cAMP tyrosine methyl ester; succinyl cGMP tyrosine methyl ester; succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in admixture or both succinyl cAMP tyrosine methyl ester and succinyl cGMP tyrosine methyl ester in separate containers, said esters labeled with radioactive iodine; a container of Reagent 2 comprising anti-cAMP serum; anti-cGMP serum; anti-cAMP and anti-cGMP serum in admixture or both anti-cAMP serum and anti-cGMP serum in separate containers; a container of Reagent 3 comprising an imidazole buffer solution of 0.1 M or higher concentration; a container of Reagent 4 comprising a material for separation; a container of Reagent 5 comprising a solution of succinic anhydride in an organic solvent; a container of Reagent 7 comprising a standard solution of cAMP; cGMP; cAMP and cGMP in admixture or both cAMP and cGMP in separate containers.
Claim 3
Dependent Claim
26 words
An assay kit as claimed in claim 1 in which the pH value of the imidazole buffer solution of Reagent 3 is from 5 to 8.
Claim 4
Dependent Claim
21 words
An assay kit as claimed in claim 1 in which the imidazole buffer solution of Reagent 3 contains a phosphodiesterase inhibitor.
Claim 5
Dependent Claim
21 words
An assay kit as claimed in claim 1, in which the organic solvent for succinic anhydride of Reagent 5 is dioxane.
Claim 6
Dependent Claim
29 words
An assay kit as claimed in claim 1 in which the organic tertiary amine of Reagent 6 is a member selected from the group consisting of 4-morpholino-N,N'-dicyclohexylcarboxamidine and triethylamine.
Claim 7
Dependent Claim
48 words
An assay kit as claimed in any one of claim 1 in which the material for separation of Reagent 4 is a member selected from dextran-coated charcoal, dextran-coated charcoal dispersion, ammonium sulfate, ammonium sulfate solution, polyethylene glycol, polyethylene glycol solutin, anti gamma-globulin serum and anti gamma-globulin serum solution.
Claim 8
Dependent Claim
43 words
An assay kit as claimed in claim 1, in which the organic solvent for succinic anhydride of Reagent 5 is a member selected from the group consisting of pyridine, dioxane, acetone, acetonitrile, dimethylsulfoxide, diethylene glycol dimethyl ether, hexamethylphosphorictriamide, tetrahydropyrane, and methyl cellosolve acetate.
Claim 9
Dependent Claim
13 words
An assay kit according to claim 7 wherein the organic solvent is dioxane.
Claim 10
Dependent Claim
13 words
An assay kit according to claim 7 wherein the organic solvent is hexamethylphosphorictriamide.
Claim 11
Independent Claim
179 words
A method of using an assay kit for assaying cAMP, cGMP or both which comprises: mixing Reagent 5 comprising a solution of succinic anhydride in an organic solvent and Reagent 6 comprising an organic tertiary amine; adding the resulting mixture respectively to a test specimen and Reagent 7 comprising a standard solution of cAMP; cGMP; cAMP and cGMP in admixture or both cAMP and cGMP in separate containers thereby to succinylate the cAMP, cGMP or both; diluting the resulting products respectively with Reagent 3 comprising an imidazole buffer solution of 0.1 M or higher concentration and thereafter mixing the same respectively with Reagent 1 comprising cAMP tyrosine methyl ester, succinyl cGMP tyrosine methyl ester or both; mixing the resulting mixtures respectively with Reagent 2 comprising anti-cAMP serum, anti-cGMP serum, or both thereby to cause an antigen-antibody reaction in each of the mixtures; adding respectively to the resulting product Reagent 4 comprising a material for separation thereby to separate antigen-antibody complex thus formed; and measuring the radioactivity of the antigen-antibody complex thereby to accomplish ultramicro-assay of cAMP, cGMP or both.
Claim 12
Independent Claim
179 words
A method of using an assay kit for assaying cAMP, cGMP or both which comprises: mixing Reagent 5 comprising a solution of succinic anhydride in an organic solvent and Reagent 6 comprising an organic tertiary amine; adding the resulting mixture respectively to a test specimen and Reagent 7 comprising a standard solution of cAMP; cGMP; cAMP and cGMP in admixture or both cAMP and cGMP in separate containers thereby to succinylate the cAMP, cGMP or both; diluting the resulting products respectively with Reagent 3 comprising an imidazole buffer solution of 0.1 M or higher concentration and thereafter mixing the same respectively with Reagent 1 comprising cAMP tyrosine methyl ester, succinyl cGMP tyrosine methyl ester or both; mixing the resulting mixtures respectively with Reagent 2 comprising anti-cAMP serum, anti-cGMP serum, or both thereby to cause an antigen-antibody reaction in each of the mixtures; adding respectively to the resulting product Reagent 4 comprising a material for separation thereby to separate antigen-antibody complex thus formed; and measuring the radioactivity of the antigen-antibody complex thereby to accomplish ultramicro-assay of cAMP, cGMP or both.
Claim 13
Dependent Claim
48 words
A method of using an assay kit for assaying cAMP, cGMP or both as claimed in claim 10 in which the mixing of Reagent 5 and Reagent 6 is carried out immediately prior to the addition of the resulting mixture thereof to the test specimen and Reagent 7.
Claim 14
Dependent Claim
142 words
In a method for assaying cAMP, cGMP or both contained in organisms wherein cAMP, cGMP or both in a sample taken from an organism are succinylated, the succinylated cAMP, cGMP or both are caused to undergo an antigen-antibody reaction with anti-cAMP serum, anti-cGMP serum or both in the presence of succinyl cAMP tyrosine methyl ester, succinyl cGMP tyrosine methyl ester labeled with radioactive iodine, or both which undergo an antigen-antibody reaction with the anti-cAMP serum, anti-cGMP serum or both, the antigen-antibody complex thus formed is separated, and the radioactivity of the antigen-antibody complex or free antigen is measured thereby to determine the content of cAMP, cGMP or both in the organism based on the radioactivity thus measured, the improvement which comprises the use, as a reaction medium for the antigen-antibody reaction, of an imidazole buffer solution of 0.1 M or higher concentration.
Claim 15
Dependent Claim
142 words
In a method for assaying cAMP, cGMP or both contained in organisms wherein cAMP, cGMP or both in a sample taken from an organism are succinylated, the succinylated cAMP, cGMP or both are caused to undergo an antigen-antibody reaction with anti-cAMP serum, anti-cGMP serum or both in the presence of succinyl cAMP tyrosine methyl ester, succinyl cGMP tyrosine methyl ester labeled with radioactive iodine, or both which undergo an antigen-antibody reaction with the anti-cAMP serum, anti-cGMP serum or both, the antigen-antibody complex thus formed is separated, and the radioactivity of the antigen-antibody complex or free antigen is measured thereby to determine the content of cAMP, cGMP or both in the organism based on the radioactivity thus measured, the improvement which comprises the use, as a reaction medium for the antigen-antibody reaction, of an imidazole buffer solution of 0.1 M or higher concentration.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-09-18 | 1982-03-20 | 1982-09-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-09-18 | 1986-03-20 | 1986-09-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-09-18 | 1990-03-20 | 1990-09-19 | $7700.00 | Window Closed / Lapsed |